Note 10 - Segment Information: Schedule of Segment Reporting Information, by Segment (Tables)

6 Months Ended

Oct. 31, 2017

Tables/Schedules

Schedule of Segment Reporting Information, by Segment

	Three Months Ended October 31,			Six Months Ended October 31,
	2017	2016		2017	2016
Revenues:
Chinese medicine - third party	$        741,954	$        706,115		$ 1,423,220	$      1,380,122
Chinese medicine - related party	0	0		0	0
Total Chinese medicine	741,954	706,115		1,423,220	1,380,122
Stevioside - third party	4,082,393	2,791,223		7,076,893	4,991,995
Stevioside - related party	145,824	1,948,631		267,380	3,462,369
Total Stevioside	4,228,217	4,739,854		7,344,273	8,454,364
Total segment and consolidated revenues	$     4,970,171	$     5,445,969		$ 8,767,493	$      9,834,486
Interest (expense) income:
Chinese medicine	$                194		$                 20	$                 356	$                   73
Stevioside	(118,154)		(88,584)	(235,615)	(169,971)
Total segment and consolidated interest expense	$      (117,960)		$       (88,564)	$       (235,259)	$       (169,898)
Depreciation and amortization:
Chinese medicine	$          69,648		$         72,856	$         137,430	$        148,049
Stevioside	348,597		357,468	731,203	700,999
Total segment and consolidated depreciation and amortization	$        418,245		$       430,324	$         868,633	$        849,048
Loss before income taxes:
Chinese medicine	$      (439,194)		$     (191,545)	$       (514,908)	$       (149,896)
Stevioside	(1,158,161)		(368,871)	(1,817,038)	(827,670)
Corporate and other	(334,367)		(350,997)	(707,204)	(767,014)
Total consolidated loss before income taxes	$   (1,931,722)		$     (911,413)	$    (3,039,150)	$   (1,744,580)